Registration Document/Universal Registration Document

Shares and Voting Rights Declaration

Treasury stock

The Company holds 124,322 own ordinary shares with a par value of €0.15 each. The shares are recorded as treasury stock in the financial statements and the number and movements during the fiscal year are disclosed in the notes to the financial statements.

Directors’ Dealings

Transactions in excess of EUR 20,000 per calendar year, executed on Company’s financial instruments by persons discharging managerial responsibilities (as referred to in Article L. 621-18-2, I of the French Monetary and Financial Code), must be reported to the French Financial Markets Authority (AMF). The AMF will publish the transactions.

The publication of such transactions is available on the website of the French Financial Markets Authority (AMF).

Rights Issues

PIPE 2018

On September 27, 2018 Valneva announced that it has raised €50 million of gross proceeds in a private placement of its ordinary shares.

Rights Issue 2015

Valneva announces the launch of a capital increase with shareholders preferential subscription rights of approximately EUR 45 million.

Rights Issue 2013

Merger 2013

In December 2012, the Management Boards of Vivalis SA and Intercell AG announced that they have agreed the terms of a merger to create the newly-named Valneva SE, a leading European biotechnology company in vaccines and antibodies.

The shareholders of both Intercell and Vivalis have approved the merger in their respective shareholder meetings on February 27, 2013 and March 7, 2013.

The merger was completed on May 28, 2013.